We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You will be told at the end of this month about SD
That’s when GSK has run out of time to petition again
19 p approx 155 million pounds divided by 596 million shares
GLA
Can anyone enlighten on when Special divi may be paid as company timeline is a bit vague (2021) and educate me as to how the figure of 19p that is eluded to. Thanks to those who offer an insight. FD
I will do the gunning with pleasure
I do hate abysmal up theyrearse directors and this company as a multitude of them
Too many for the pier the beach will be ok
To repeat what I said on ADVFN earlier:
While Vec's primary focus is on bringing new inhaled medicines to market, if the board can't (or won't) direct resources to meet what will be the largest single spike in global demand for an inhaled medicine since the invention of the inhaler, they all want lining up on Bridlington Pier and machine gunning into the North Sea.
The management are to stupid to get on the ball
Always late too the party
Institutions are selling also
Got rid of a certain amount on latest spike
Will sit tight but not overly happy with the situation and the selling although 120 will see my departure
GLA
BBC News - Covid: Asthma drug 'speeds up recovery at home'
https://www.bbc.co.uk/news/health-56717486
Hopefully Vec will be at the forefront of the global supply of the inhaled budesonide. Demand will likely rocket, especially in Europe given their dreadful vaccine rollout.
VEC and HIK Both rising in tandem
Leaky ship about the generic Advil in the states i would think
Big paydays in view GLA
The only volcano I see erupting is in Iceland.... this here seems to be a damp squib!
I'm sure someone is doing their best to make us sell through boredom, not me no sirree !
Hopefully the nex,.t spike will be 150
Is in command for sure
Someone using the volume to their advantage
I am out on the next spike
Vectura need a clear out of waste management just like GSK
Cannot believe how these wasters get the chance at the top
Take the wages vanker
Or you could focus on the negative ?????
Tax man will like that!!
You stand to make £115k from the upcoming special div, which pretty much covers your original stake. Fair play to you!
nice one :)
I've had 600k shares in Vectura for> 15 years. Bought when they were 26pKept with them as a pension potHope to them at £2 soon
I stick to my prediction
ReRating is imminent 130pence will be swift With 150pence Very Soon
200pence by the end of 2021 is Viable
Make no mistake of the numbers
Or there Targets
2021 is the volcano year for Vectura
A headline profit instead of a loss due to right downs makes a nice change albeit due the GSK monies, it's looking like that saga is finally over although they still have the supreme court option available, although it should be noted we have always been profitable just the accounting from Skypharma merger clouding that.
VEC's transition being put in place as they change their direction only very small revenues generated at present, but will increase.
Backed by steady existing revenues to allow this transaction, pity about the special dividend I would of liked to see an acquisition, but I will accept the cash.
Steady as she goes although the market seems underwhelmed when a lot of comps are adjusting their banking covenants left right and center is baffling.
Hope to see some tick up as the days pass by and our results sink in and some jop on board for the Divi.
Yes of course
Not even confirmed yet
Not sure how you got to 150p - I got 14p. Out by a factor of 10. You divide the $115m by the no of share and convert c to p.
I’ve held since skypharma days and the SP performance has been like walking through treacle.
I’ll hold in anticipation of better valuation but wish I bought more when it was well below £1.
Great set of results here, surprised that they have not risen more...Chaps quick question - would buying today qualify for receiving the special divi? Regards
The graph is a thing of beauty. If this holds up then we must surely see 1.35 to 1.40 before breaking down again
Growing business measured by revnue, increasingly profitable after excluding exceptional income, clearly everyone can do their own calculations but mine tell me that with special dividend this should be well north of 150p - glad I bought in recently.
Royalty income, litigation win see Vectura beat expectations
Thu, 18th Mar 2021 07:43
(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.
The FTSE 250 inhaled pharmaceuticals company said product supply revenue decreased 4.4% year-on-year in 2020 to £109.9m, although product supply revenues from 'flutiform' were marginally ahead of guidance at £95.8m.
Development services revenues, meanwhile, advanced 4.4% to £11.9m, which the board put down to a contribution from new contract development and manufacturing organisation (CDMO) agreements in the second half.
Royalty and other marketed revenues rocketed 32.6% to £68.8m, driven by milestones and fourth quarter GlaxoSmithKline 'Ellipta' royalties of £6.5m, following a successful outcome from litigation in the United States.
Gross profit increased 6.4% to £101.4m, and adjusted EBITDA was 41.7% firmer at £61.5m, which was also put down to the increase in royalty and other marketed revenues, and a material decrease in research and development investment.
Operating profit came in at £132.8m, swinging from a loss of £27m in 2019, which was driven by the recognition of £121.1m of exceptional income for damages and interest associated with the enforcement of a patent covering three US GlaxoSmithKline 'Ellipta' products, and improved adjusted EBITDA performance.
Vectura said it maintained strong liquidity, with closing cash and cash equivalents rising to £78.6m from £74.1m a year earlier, reflecting free cash flow generation of £24.1m and a share buyback of about £16.4m during the year.
On the operational front, Vectura described a "strong" execution of its strategy, with a new business development team now established with a presence on the east and west coasts of the US, as well as Europe and the UK.
A total of 18 new CDMO contracts were signed during 202, contributing £3m to second half revenues.
Vectura also made progress across its co-development pipeline, with approval of 'VR315', its generic 'Advair' programme in partnership with Hikma, coming in December and triggering milestone payments of $11m.
The approval of 'Enerzair Breezhaler' in Japan and Europe, meanwhile, triggered milestones of $6.25m.
Vectura said its "operational transformation" was ongoing, with a phased transition of research and development operations from Switzerland to the UK now underway.
Since the year ended, and following a review of the firm's capital allocation priorities, the board said it had approved in principle a special dividend of around £115m, to be paid during 2021.
"The business has performed well during 2020, delivering financial performance ahead of expectations," said chief executive officer Will Downie.
"We are pleased with the progress we have made against our inhalation CDMO strategy, signing 18 deals during 2020, with £3.0m revenue recognised in the sec